How Real-Time Rx Graph boosts pharma targeting with margin insights

The #pharma industry is evolving at an unprecedented pace, with #DTC (Direct-to-Consumer) and #DTP (Direct-to-Patient) models continuing to take center stage. At Archbow, we’re committed not only to tracking these changes but also to empowering our clients with the insights and strategies they need to stay ahead. Our latest blog explores the ongoing evolution of DTC models and the impact of telemedicine on the future of pharma: https://lnkd.in/et9PcqGn Archbow's subject matter experts are committed to continuous learning, ensuring our clients stay ahead in a rapidly evolving marketplace—stay tuned for more insights. #Telemedicine #PatientAccess #ArchbowConsulting

A pharma team recently shared how they approached their first treatment launch. With limited budget, they focused on using real-world data to guide decisions. Using NorstellaLinQ from Norstella, they prioritized HCPs in real time and built engagement plans based on actual market activity. They also pulled in physician notes and EMRs to identify patients earlier in their journey. This is a great example of how data can support strategy when resources are tight. Learn more: https://vist.ly/47nmx

𝐆𝐨𝐮𝐭 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐠𝐨𝐮𝐭 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟑.𝟏𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟒, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟕.𝟎% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟓 𝐭𝐨 𝟐𝟎𝟑𝟒. 🔗𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞:https://lnkd.in/dedsWURB 𝐀𝐈 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐆𝐨𝐮𝐭 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 ✔AI-based gout management systems significantly reduce CKD progression and improve serum urate target achievement compared to traditional EMR systems. ✔Real-time data integration through mobile apps and lab tools enhances patient adherence and reduces gout flare frequency. ✔AI enables precision medicine using pharmacogenomic profiling and wearable urate monitors to personalize treatment strategies. ✔AI-powered digital health platforms, including telemedicine and remote monitoring, expand access, support dynamic treatment adjustments, and drive market growth. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dPJEkSRD #GoutTherapeutics #GoutTreatment #HealthcareInnovation #Pharmaceuticals #ChronicDiseaseManagement #ArthritisCare #MedicalResearch #DrugDevelopment #HealthcareMarket #PatientCare #GlobalPharma #TherapeuticsMarket #GoutManagement #MedicalAdvancements #HealthcareTrends

Most pharma brands still target prescribers by volume. But volume ≠ value. We found that if you prioritize prescribers based on their contribution margin rather than volume, you can double your contribution margin. The traditional model assumes: High-volume prescribers = high-value targets More scripts = more margin Bigger practices = bigger opportunity The reality our Real-Time Rx Graph shows: • Contribution margin varies wildly across prescribers • Patient support, channel fees, and PBM rebates dramatically impact profitability • Small practices can deliver higher margins than large ones When we rebuilt one client's target HCP list using real-time contribution margin data, their top 1,400 physicians represented 2x the contribution margin versus legacy volume-based methodologies. It's time to rethink how we define commercial success. Get the complete framework for transitioning from volume to margin-based targeting, including detailed case studies and implementation strategies, in our white paper Data Boom 2.0: The Power of Real-Time Data: https://lnkd.in/eehBB3Q5 If you want to double brand value, the easiest way is to target based on contribution margin instead of volume. #Pharma #CommercialStrategy #ROI #DataDriven

Digital health technologies are transforming clinical trials. We have all the tools to collect vast amounts of data, from wearables to mobile apps. This allows us to make trials more patient centric and gather rich, continuous evidence of a treatment's impact. The real challenge is moving beyond low resolution insights to high resolution insights. It's about combining objective clinical measurements with the subjective lived experience of the patient. This is how we prove a product's true value in the real world. #DigitalHealth #ClinicalTrials #PatientCentricity #RealWorldEvidence #HealthData

Clinakos Inc. had the opportunity to engage with the FDA’s recent webinar on Regulatory Submissions with Real-World Evidence (RWE), gaining invaluable insights on the evolving landscape of drug and device approvals. The sessions underscored how #RWE is transforming regulatory science by enabling approvals in rare diseases and expanding indications for medical devices through trusted, patient-centered data. Highlights include: 🌟 The Advancing RWE Program’s selective collaboration approach—accepting only those studies with rigorous design and data quality. 🌟 Breakthrough therapies like Lenelisib for Metachromatic Leukodystrophy and Orencia for acute GVHD prevention, highlighting the vital role of natural history cohorts and sibling comparators. 🌟 Abbott’s spinal cord stimulation devices case study showed how real-world safety data from over 36,000 patients expands treatment options for diabetic peripheral neuropathy. 🌟 Critical themes: early and ongoing FDA engagement, public-private partnerships, transparency, and methodological innovation—ranging from hybrid trials to AI-powered data analytics. 🌟 The Sentinel 3.0 initiative and cross-agency efforts are setting the stage for better data access, quality, and harmonization across conditions and geographies. At Clinakos, our mission is aligned with these priorities. Our technology-driven approach harnesses Integrated Patient Data™ combined with Medically Smart AI™ to generate actionable evidence that meets regulatory expectations, accelerates access, and fosters health equity. Real-world evidence is reshaping the future of healthcare innovation—Clinakos is proud to help drive this transformation. 📲 Stay connected—follow Clinakos Inc. for the latest news and updates #Healthcare #FDA #RareDisease

In today’s pharma landscape, patient-centricity isn’t a buzzword — it’s a business imperative. 🌿 As regulators and patients alike demand genuine involvement in shaping therapies, traditional engagement models are no longer enough. That’s where Virtual Advisory Boards (VABs) come in — transforming fragmented feedback into actionable dialogue that drives better clinical, commercial, and real-world outcomes. Discover how virtual engagement platforms like MphaR’s Virtual Advisory Board empower pharma to operationalize patient-centricity at scale — bridging the gap between data and meaningful decision-making. 🔗 https://lnkd.in/dEchCGQX #PatientCentricity #VirtualAdvisoryBoard #PharmaInnovation #DigitalEngagement #MedicalAffairs

**Insights!** The In Vitro Diagnostics (IVD) quality control market is on a powerful upward trajectory, projected to reach a remarkable $2.15 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.5%. This isn't just a statistic—it's a reflection of how communities and healthcare professionals are prioritizing accuracy and reliability in diagnostics. At Egreenews, our team understands that these advancements in IVD quality control are vital for healthcare providers, ensuring they can deliver precise results to patients. As our founder, Hugi Hernandez, emphasizes, the intersection of innovation and quality is essential for building trust in healthcare systems. The growth of this market underscores a collective commitment to enhancing patient care through robust quality management practices. This surge isn't merely a market trend; it represents the health of communities. Reliable diagnostic tools empower healthcare professionals to make informed decisions, leading to better outcomes for patients nationwide. The dedication to elevating standards in quality control highlights the essential role that professionals and organizations play in shaping a healthier future. As we continue to adapt and innovate, it's vital to remember that every advancement in our industry can have a profound impact on individuals' lives. Let's prioritize quality, foster collaboration, and empower one another to reach new heights in healthcare excellence. #InVitroDiagnostics #HealthcareInnovation #QualityControl #PatientCare #Egreenews

From breakthrough innovations and AI use cases to the shifting drug pricing dynamics, here are five healthcare trends from the industry's top companies. #Healthcare #HealthcareInnovation #HealthTech

From breakthrough innovations and AI use cases to the shifting drug pricing dynamics, here are five healthcare trends from the industry's top companies. #Healthcare #HealthcareInnovation #HealthTech